![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Lu, Yen-Shen; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young-Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan und Tripathy, Debu
(2022):
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 5: S. 851-859
2021
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock-Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Villanueva Vazquez, Rafael; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu und Lu, Yen-Shen
(2021):
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
In: Jco Precision Oncology, Bd. 5: S. 1408-1420
2016
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe und Piccart-Gebhart, Martine
(2016):
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 3: S. 357-366